VanEck Australian Floating Rate ETF vs Hims and Hers Health Inc — how do they compare? VanEck Australian Floating Rate ETF trades at $50.97, while Hims and Hers Health Inc trades at $34.17 (market cap $8.60B). The key difference: VanEck Australian Floating Rate ETF is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals.
| FLOT | HIMS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $51.09 | $66.18 |
52-Week Low | $50.72 | $14.52 |
Market Cap | — | $8.60B |
Enterprise Value | — | $8.98B |
Signals from Pluang's Aura AI — not financial advice
FLOT (iShares Floating Rate Bond ETF) trades at $50.97, showing minimal daily movement with a neutral technical signal. The ETF focuses on high-quality floating rate bonds with a 4.0% SEC yield, positioning it as a defensive holding amid rising rate expectations. Recent dividends of $0.17-$0.18 reflect steady income generation, while technical indicators show mixed signals with bullish moving averages but bearish ADX readings.
The outlook remains stable with potential upside if the Federal Reserve implements rate hikes later in 2026, which would boost FLOT's yield. However, the ETF faces headwinds from inflation pressures and geopolitical tensions affecting Treasury yields. Current neutral sentiment suggests FLOT serves as a cash parking vehicle rather than a growth investment, with limited price appreciation potential but reliable income generation.
Hims & Hers Health trades at $34.78, down 1.05% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. Fundamentally, the company reported $2.35B revenue in 2025 but faces profitability challenges with a negative net income margin of -0.56% and elevated valuation ratios including a P/E of 57.14. Recent news highlights expansion in weight-loss therapies and international markets, with Q2 2026 earnings due August 10, 2026.
The outlook remains cautiously optimistic with analyst consensus at Buy (35%) and a $33.57 price target near current levels. Key opportunities include GLP-1 therapy growth and subscriber additions, while risks involve profitability pressures, competitive threats, and reliance on regulatory approvals. The stock's performance hinges on execution in high-margin segments and cost management amid expansion.
Trailing returns across standard periods
Latest headlines on both assets
FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →